The Fort Worth Press - Treatment improves cognition in Down Syndrome patients

USD -
AED 3.672495
AFN 64.491965
ALL 80.819685
AMD 361.12818
ANG 1.789785
AOA 916.999774
ARS 1524.755904
AUD 1.421555
AWG 1.80125
AZN 1.698006
BAM 1.741787
BBD 2.015015
BDT 123.745402
BGN 1.747831
BHD 0.377604
BIF 3000.997453
BMD 1
BND 1.278059
BOB 11.730759
BRL 5.027097
BSD 1.000472
BTN 94.559477
BWP 13.70595
BYN 2.971479
BYR 19600
BZD 2.012094
CAD 1.404485
CDF 2315.999766
CHF 0.823855
CLF 0.024781
CLP 975.290259
CNY 6.67805
CNH 6.67482
COP 3182.19
CRC 455.529135
CUC 1
CUP 24.010794
CVE 98.199695
CZK 21.60605
DJF 178.150632
DKK 6.653225
DOP 61.440772
DZD 134.635978
EGP 54.356702
ERN 15
ETB 163.87083
EUR 0.89012
FJD 2.2538
FKP 0.747587
GBP 0.74605
GEL 2.589936
GGP 0.747587
GHS 11.660299
GIP 0.747587
GMD 73.504156
GNF 8854.987666
GTQ 7.645587
GYD 209.311853
HKD 7.847135
HNL 26.857072
HRK 6.7076
HTG 131.084908
HUF 324.795004
IDR 18048
ILS 3.09091
IMP 0.747587
INR 94.43705
IQD 1516.6493
IRR 1832375.000402
ISK 121.260321
JEP 0.747587
JMD 158.780625
JOD 0.709021
JPY 157.860501
KES 129.849897
KGS 87.450106
KHR 4068.146802
KMF 439.497294
KPW 899.999961
KRW 1325.830107
KWD 0.31006
KYD 0.833753
KZT 446.890557
LAK 22518.390538
LBP 89591.044298
LKR 332.14739
LRD 170.580744
LSL 16.412051
LTL 2.95274
LVL 0.60489
LYD 6.419294
MAD 9.819615
MDL 17.998442
MGA 4521.489767
MKD 54.903951
MMK 2099.21541
MNT 3597.533576
MOP 8.085932
MRU 40.128421
MUR 47.309704
MVR 15.460077
MWK 1734.751129
MXN 18.485085
MYR 4.081297
MZN 63.898647
NAD 16.412051
NGN 1332.179821
NIO 36.816372
NOK 9.35655
NPR 151.295341
NZD 1.75665
OMR 0.384516
PAB 1.000481
PEN 3.438421
PGK 4.479652
PHP 63.302028
PKR 276.89823
PLN 3.883845
PYG 5756.677086
QAR 3.647261
RON 4.7506
RSD 104.566998
RUB 81.872113
RWF 1478.615162
SAR 3.748965
SBD 8.07458
SCR 13.833364
SDG 601.501249
SEK 9.878075
SGD 1.27711
SHP 0.7473
SLE 23.920425
SLL 20969.504398
SOS 571.749178
SRD 37.661494
STD 20697.981008
STN 21.819089
SVC 8.754392
SYP 13001.999685
SZL 16.418788
THB 33.573502
TJS 9.214157
TMT 3.51
TND 2.986543
TOP 2.40776
TRY 49.602435
TTD 6.792416
TWD 32.365497
TZS 2644.999919
UAH 45.047334
UGX 4207.076509
UYU 40.164934
UZS 11975.562621
VES 879.788905
VND 25856.5
VUV 119.136032
WST 2.774679
XAF 583.880316
XAG 0.017358
XAU 0.00024154356
XCD 2.70255
XCG 1.803058
XDR 0.707052
XOF 583.880316
XPF 106.20998
YER 236.095747
ZAR 16.379565
ZMK 9001.201607
ZMW 20.069287
ZWL 321.999592
SSP 5787.554334
MXV 2.08653
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Treatment improves cognition in Down Syndrome patients
Treatment improves cognition in Down Syndrome patients / Photo: © AFP/File

Treatment improves cognition in Down Syndrome patients

A new hormone treatment improved the cognitive function of six men with Down Syndrome by 10-30 percent, scientists said Thursday, adding the "promising" results may raise hopes of improving patients' quality of life.

Text size:

However the scientists emphasised the small study did not point towards a cure for the cognitive disorders of people with Down Syndrome and that far more research is needed.

"The experiment is very satisfactory, even if we remain cautious," said Nelly Pitteloud of Switzerland's Lausanne University Hospital and co-author of a new study in the journal Science.

Down Syndrome is the most common genetic form of intellectual disability, occurring in around one in 1,000 people, according to the World Health Organization.

Yet previous research has failed to significantly improve cognition when applied to people with the condition, which is why the latest findings are "particularly important", the study said.

Recent discoveries have suggested that how the gonadotropin-releasing hormone (GnRH) is produced in the brain can affect cognitive functioning such as memory, language and learning.

GnRH hormones regulate how much testosterone and estrogen is produced and increased levels of it help spur puberty.

"We wondered if this hormone could play any role in establishing the symptoms of people with Down Syndrome," said Vincent Prevot, study co-author and head of neuroscience research at France's INSERM institute.

- Mice research -

The team first established that five strands of microRNA regulating the production of GnRH were dysfunctional in mice specifically engineered for Down Syndrome research.

They then demonstrated that cognitive deficiencies -- as well as loss of smell, a common symptom of Down Syndrome -- were linked to dysfunctioning GnRH secretion in the mice.

The team then gave the mice a GnRH medication used to treat low testosterone and delayed puberty in humans, finding that it restored some cognitive function and sense of smell.

A pilot study was conducted in Switzerland involving seven men with Down Syndrome aged 20 to 50.

They each received the treatment through their arm every two hours over a period of six months, with the drug delivered in pulses to mimic the hormone's frequency in people without Down Syndrome.

Cognition and smell tests were carried out during the treatment, as were MRI scans.

Six of the seven men showed improvement in cognition with no significant side effects -- however none showed a change in their sense of smell.

"We have seen an improvement of between 10-30 percent in cognitive functions, in particular with visuospatial function, three-dimensional representation, understanding of instructions as well as attention," Pitteloud said.

The patients were asked to draw a simple 3D bed at several stages throughout the therapy. Many struggled at the beginning but by the end the efforts were noticeably better.

- 'Improve quality of life' -

The authors acknowledged some limitations of the study, including its size and that the choice of patients was "pushed by their parents".

"The clinical trial only focused on seven male patients -- we still have a lot of work to do to prove the effectiveness of GnRH treatment for Down Syndrome," Pitteloud said.

A larger study involving a placebo and 50 to 60 patients, a third of them women, is expected to begin in the coming months.

"We are not going to cure the cognitive disorders of people with Down Syndrome, but the improvement seen in our results already seems fundamental enough to hope to improve their quality of life," Pitteloud said.

Fabian Fernandez, an expert in cognition and Down Syndrome at the University of Arizona who was not involved in the research, hailed the "tour de force study".

He told AFP that while it is "difficult to envision" how such an intensive treatment could be used for young people, it might be better suited to delay the Alzheimer's disease-related dementia suffered by many adults with Down Syndrome.

It was also difficult to predict how such an improvement could impact the lives of people with the condition, he said.

"For some, it could be significant, however, as it would enable them to be more independent with daily living activities such as maintaining and enjoying hobbies, finding belongings, using appliances in the home, and travelling alone."

P.McDonald--TFWP